PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

Manuscript NO: 64621

Title: COVID-19 in liver transplant patients. Clinical and therapeutic aspects

Reviewer’s code: 05301926

Position: Peer Reviewer

Academic degree: MD

Professional title: Professor

Reviewer’s Country/Territory: Japan

Author’s Country/Territory: Spain

Manuscript submission date: 2021-02-21

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-08 10:26

Reviewer performed review: 2021-04-08 10:49

Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ Y] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[ ] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ Y] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ Y] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
</tr>
</tbody>
</table>

| Re-review          | [ ] Yes                   | [ Y] No                        |

| Peer-reviewer      | Peer-Review: [ Y] Anonymous | [ ] Onymous |
| statements         |                          | Conflicts-of-Interest: [ ] Yes | [ Y] No |
SPECIFIC COMMENTS TO AUTHORS
This is an interesting review, however, too long,
Name of journal: World Journal of Hepatology

Manuscript NO: 64621

Title: COVID-19 in liver transplant patients. Clinical and therapeutic aspects

Reviewer’s code: 05635503

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer’s Country/Territory: Italy

Author’s Country/Territory: Spain

Manuscript submission date: 2021-02-21

Reviewer chosen by: Man Liu

Reviewer accepted review: 2021-05-07 11:02

Reviewer performed review: 2021-05-07 12:35

Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Peer-reviewer statements

Conflicts-of-Interest: Yes | No

Peer-Review: Yes | Anonymous | Onymous
SPECIFIC COMMENTS TO AUTHORS
COVID-19 has high morbidity and mortality for transplant candidates. The data on the relationship between immunosuppressive therapy and COVID-19 in LT recipients during this pandemic are still insufficient. Older age and post-transplant comorbidities showed to have a larger role than immunosuppression status. COVID-19 therapies and vaccinations seem to be well tolerated in pre and postliver transplant patients (with few exceptions). All this is clear and already consolidated in the literature. The present paper also highlights that Tacrolimus could be protective, but anti-proliferative such as MMF should be avoided. The situation during the pandemic is evolving rapidly, and recommendations need to evolve as well. As we learn more about how the COVID-19 pandemic impacts the care of patients before and after LT, updates are beneficial. The paper looks promising but, in its actual form, it is verbose and redundant. Revision of the manuscript is required to focus on novel conclusions.
# PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology  
**Manuscript NO:** 64621  
**Title:** COVID-19 in liver transplant patients. Clinical and therapeutic aspects  
**Reviewer’s code:** 05072261  
**Position:** Peer Reviewer  
**Academic degree:** MD  
**Professional title:** Doctor, Occupational Physician  
**Reviewer’s Country/Territory:** Italy  
**Author’s Country/Territory:** Spain  
**Manuscript submission date:** 2021-02-21  
**Reviewer chosen by:** Man Liu  
**Reviewer accepted review:** 2021-05-06 14:57  
**Reviewer performed review:** 2021-05-14 16:55  
**Review time:** 8 Days and 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ ] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[ ] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peer-reviewer statements</td>
<td>Peer-Review: [ ] Anonymous</td>
<td>[ ] Onymous</td>
<td>Conflicts-of-Interest: [ ] Yes</td>
<td>[ ] No</td>
<td></td>
</tr>
</tbody>
</table>
Dear Authors,

this is a well written review about COVID-19 in liver transplant patients. Since March 2020 many studies have been published on this issue, and you have done a good job of literature search. Transplant recipients are not so many in the majority of the articles published, and there are few studies with high scientific level. I have some comments:

- the first section Early experience is too long, it would be better to summarize the case reports only with citation, maybe it was interesting to underline to categories of patients: long term transplanted vs early liver recipients.
- For the section COVID-19 and liver please add the citation "Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy, J hep "
  https://doi.org/10.1016/j.jhep.2021.04.050 about the correlation between endotheliopathy IL-6 correlated and liver injury;
RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Hepatology
Manuscript NO: 64621
Title: COVID-19 in liver transplant patients: Clinical and therapeutic aspects
Reviewer’s code: 05635503
Position: Peer Reviewer
Academic degree: MD
Professional title: Doctor
Reviewer’s Country/Territory: Italy
Author’s Country/Territory: Spain
Manuscript submission date: 2021-02-21
Reviewer chosen by: Ya-Juan Ma
Reviewer accepted review: 2021-07-16 17:19
Reviewer performed review: 2021-07-18 21:30
Review time: 2 Days and 4 Hours

Scientific quality
[ ] Grade A: Excellent  [ ] Grade B: Very good  [ Y] Grade C: Good
[ ] Grade D: Fair  [ ] Grade E: Do not publish

Language quality
[ ] Grade A: Priority publishing  [ Y] Grade B: Minor language polishing
[ ] Grade C: A great deal of language polishing  [ ] Grade D: Rejection

Conclusion
[ ] Accept (High priority)  [ Y] Accept (General priority)
[ ] Minor revision  [ ] Major revision  [ ] Rejection

Peer-reviewer statements
Peer-Review: [ ] Anonymous  [ Y] Onymous
Conflicts-of-Interest: [ ] Yes  [ Y] No

SPECIFIC COMMENTS TO AUTHORS
Suggested revisions accomplished.